Linked Life Data

17012906

Source:http://linkedlifedata.com/resource/pubmed/id/17012906

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-10-12
pubmed:abstractText
Cancer carbohydrate antigens have been surprisingly potent targets for immune recognition and attack by antibodies, both because of their abundance at the cell surface and their immunogenicity. Antibodies are ideally suited for eradicating pathogens from the bloodstream and from early tissue invasion. Passively administered and vaccine induced antibodies have accomplished this, eliminating circulating tumor cells and systemic or intraperitoneal micrometastases in a variety of preclinical models. A series of carbohydrate cancer cell-surface differentiation antigens have now been identified and synthesized. Antibodies against each can be induced in the majority of vaccinated patients using KLH conjugate vaccines with a potent saponin immunological adjuvant. Polyvalent vaccines will probably be required due to tumor cell heterogeneity, heterogeneity of the human immune response and the correlation between overall antibody titer against tumor cells and antibody effector mechanisms. Trials testing the clinical impact of these polyvalent vaccines in the adjuvant setting are planned for the near future.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1554-8600
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
137-43
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:articleTitle
Cancer vaccines targeting carbohydrate antigens.
pubmed:affiliation
Laboratory of Tumor Vaccinology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural